Fortress Biotech, Inc. (NASDAQ:FBIO) Given Average Recommendation of “Moderate Buy” by Analysts

Fortress Biotech, Inc. (NASDAQ:FBIOGet Rating) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.60.

A number of research firms have recently weighed in on FBIO. B. Riley reduced their target price on shares of Fortress Biotech from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, July 14th. Cantor Fitzgerald reissued a “buy” rating and set a $6.00 target price on shares of Fortress Biotech in a research report on Friday, May 13th. LADENBURG THALM/SH SH began coverage on shares of Fortress Biotech in a research report on Thursday. They set a “buy” rating and a $6.00 target price for the company. Finally, StockNews.com raised shares of Fortress Biotech from a “sell” rating to a “hold” rating in a report on Thursday, May 19th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC purchased a new stake in Fortress Biotech in the 4th quarter worth approximately $41,000. Advisor Group Holdings Inc. lifted its stake in Fortress Biotech by 113.0% in the 1st quarter. Advisor Group Holdings Inc. now owns 20,020 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 10,620 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in Fortress Biotech in the 4th quarter worth approximately $56,000. Envestnet Asset Management Inc. purchased a new stake in Fortress Biotech in the 1st quarter worth approximately $33,000. Finally, Mirabella Financial Services LLP purchased a new stake in Fortress Biotech in the 1st quarter worth approximately $42,000. 30.92% of the stock is owned by institutional investors.

Fortress Biotech Trading Up 6.1 %

NASDAQ:FBIO opened at $1.21 on Monday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 3.15 and a current ratio of 3.31. The firm has a market cap of $129.97 million, a price-to-earnings ratio of -1.41 and a beta of 2.10. Fortress Biotech has a 52 week low of $0.77 and a 52 week high of $3.81. The firm has a 50-day moving average price of $0.91 and a two-hundred day moving average price of $1.23.

Fortress Biotech (NASDAQ:FBIOGet Rating) last released its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.10. Fortress Biotech had a negative net margin of 88.31% and a negative return on equity of 32.56%. The firm had revenue of $23.93 million during the quarter, compared to the consensus estimate of $20.06 million. During the same period in the prior year, the firm earned ($0.11) EPS. On average, equities analysts expect that Fortress Biotech will post -0.79 earnings per share for the current fiscal year.

About Fortress Biotech

(Get Rating)

Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne.

Recommended Stories

Analyst Recommendations for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.